EphB6 receptor modulates micro RNA profile of breast carcinoma cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Bhushan, Lokesh ^a   Kandpal, Raj P ^a  

^a Western University of Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B6; MICRORNA; MIR 100; MIR 16; MIR 23A; MIR 24; MIR 26A; MIR 29A; MIRPLUS E1172; MIRPLUS E1258; UNCLASSIFIED DRUG; MESSENGER RNA;

ACTB GENE; ARTICLE; BMPR1A GENE; BMPR1B GENE; BMPR2 GENE; BREAST CARCINOMA; CANCER CELL; ELF2C2 GENE; ELF2C4 GENE; ELF4EBP2 GENE; FKABP5 GENE; FKBP1A GENE; GENE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; SIGNAL TRANSDUCTION; SMARCA5 GENE; SMARCC1 GENE; TRIB1 GENE; TRIB2 GENE; TRIB3 GENE; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NUCLEIC ACID HYBRIDIZATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPHB6; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TRANSFECTION;

EID: 79960457147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022484     Document Type: Article

References (41)

1. Kullander K, Klein R, (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3: 475-486.
2. Pasquale EB, (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
3. Fox BP, Kandpal RP, (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882-892.
4. Fox BP, Kandpal RP, (2006) Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem Biophys Res Commun 340: 268-276.
5. Fox BP, Kandpal RP, (2009) EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 28: 1706-1713.
6. Fox BP, Kandpal RP, (2008) Yeast two- hybrid assay reveals several interactors of EphB6 receptor. Open Proteomics J 1: 79-86.
7. Kandpal RP, (2010) Tyrosine kinase-deficient EphB6 receptor-dependent alterations in proteomic profiles of invasive breast carcinoma cells as determined by difference gel electrophoresis. Cancer Genomics Proteomics 7: 253-260.
8. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
9. Ryan BM, Robles AI, Harris CC, (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389-402.
10. Dalmay T, Edwards DR, (2006) MicroRNAs and the hallmarks of cancer. Oncogene 25: 6170-6175.
11. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
12. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
13. Song G, Sharma AD, Roll GR, Ng R, Lee AY, et al. (2010) MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 51: 1735-1743.
14. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611.
15. Lu J, He ML, Wang L, Chen Y, Liu X, et al. (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71: 225-233.
16. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, et al. (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24: 447-463.
17. Hassan MQ, Gordon JA, Beloti MM, Croce CM, van Wijnen AJ, et al. (2010) A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A 107: 19879-19884.
18. Chhabra R, Dubey R, Saini N, (2010) Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer 9: 232.
19. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, et al. (2010) Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 70: 7176-7186.
20. Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, et al. (2009) MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 45: 3104-3118.
21. Gebeshuber CA, Zatloukal K, Martinez J, (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10: 400-405.
22. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
23. Andersen CL, Christensen LL, Thorsen K, Schepeler T, Sorensen FB, et al. (2009) Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer 100: 511-523.
24. Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, et al. (2000) Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia 14: 1247-1252.
25. Klein A, Wessel R, Graessmann M, Jurgens M, Petersen I, et al. (2007) Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. Int J Cancer 121: 683-688.
26. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, et al. (2005) High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 7: R1186-1198.
27. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
28. Kinyamu HK, Collins JB, Grissom SF, Hebbar PB, Archer TK, (2008) Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. Mol Carcinog 47: 845-885.
29. Li L, Lou Z, Wang L, (2011) The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 104: 19-23.
30. Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, et al. (1996) Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. J Biol Chem 271: 21687-21690.
31. Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, et al. (2003) Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63: 1865-1870.
32. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, et al. (2007) Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109: 3998-4005.
33. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, et al. (2007) Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9: 820-829.
34. Zanella F, Renner O, Garcia B, Callejas S, Dopazo A, et al. (2010) Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 29: 2973-2982.
35. Miyoshi N, Ishii H, Mimori K, Takatsuno Y, Kim H, et al. (2009) Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis. Br J Cancer 101: 1664-1670.
36. Greer EL, Brunet A, (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
37. Ghayad SE, Cohen PA, (2010) Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 5: 29-57.
38. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, et al. (2011) Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood doi:10.1182/blood-2011-01-330704.
39. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
40. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, et al. (2007) A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700-2707.
41. Ramakers C, Ruijter JM, Deprez RH, Moorman AF, (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62-66.